Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer

Purpose: Because Cancer and Leukemia Group B 9741 trial showed a benefit for every 14-day administration of chemotherapy compared with every 21-day treatment, we hypothesized that even greater dose density would be more effective. We conducted a pilot trial to assess the feasibility of dose-dense ch...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 13; no. 1; pp. 223 - 227
Main Authors:	FORNIER, Monica N, SEIDMAN, Andrew D, HUDIS, Clifford, LAKE, Diana, D'ANDREA, Gabriella, BROMBERG, Jacqueline, ROBSON, Mark, VAN POZNAK, Catherine, PANAGEAS, Katherine S, ATIENZA, Marietta, NORTON, Larry
Format:	Journal Article
Language:	English
Published:	Philadelphia, PA American Association for Cancer Research 01-01-2007
Subjects:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences breast cancer Breast Neoplasms - drug therapy clinical research Cyclophosphamide - administration & dosage Epirubicin - administration & dosage Feasibility Studies Female Filgrastim Granulocyte Colony-Stimulating Factor - administration & dosage Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Paclitaxel - administration & dosage Pharmacology. Drug treatments phase I-III clinical trials Pilot Projects Recombinant Proteins Time Factors Tumors Antineoplastic agent Human Cytokine Breast cancer Malignant tumor Density Filgrastim Mammary gland diseases Alkylating agent Granulocyte colony stimulating factor Oxazaphosphinane derivatives Cyclophosphamide Nitrogen mustard Taxane derivatives Paclitaxel Adult Female Anthracyclins Adjuvant Epirubicin Woman Antimitotic Dose
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!